J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as ...

Several French companies have committed to making new investments in the Egyptian market across various sectors, including ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...

The Paris Olympics have been a showcase not only for athletic ... of using the Olympics to sell products of dubious medical value. French pharmaceutical giant Sanofi came under criticism for promoting ...

Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

Sanofi has launched a new initiative in its drive to integrate digital technologies throughout its business, setting up an accelerator based in Paris that will serve as the lynchpin of the effort.

"Its history includes some of the major scientific advances of the nineteenth and twentieth centuries…" On 18th May 1999, Sanofi and Synthélabo officially came together in Paris, France to form ...

European stocks were seeing marginal gains on Friday amid concerns about a wider Middle East conflict and ahead of the all-important U.S. jobs report due later ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to ...

The encouraging news is that Nigeria is set to take a significant step towards economic independence and energy security on ...